TREACE MEDICAL CONCEPTS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TREACE MEDICAL CONCEPTS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $212.69M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $209.36M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $187.12M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $141.84M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $94.42M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $57.37M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $39.42M | Mar 4, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $169.75M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $168.26M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $151.94M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $116.31M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $77.53M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $44.90M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $31.79M | Mar 4, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.00M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($55.74M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($49.53M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($42.82M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($20.55M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($3.67M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | ($4.27M) | Mar 4, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($54.15M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($55.69M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($51.43M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($34.84M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($16.51M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $855.0K | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | ($3.54M) | Mar 4, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.28M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $20.59M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $15.44M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $13.58M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $10.20M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $5.85M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $5.07M | Mar 4, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.97M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($37.17M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($34.58M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($30.65M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($17.19M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($4.49M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | ($7.67M) | Mar 4, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.52M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $11.59M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $11.46M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $14.84M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.71M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.07M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $1.21M | Mar 4, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $190.58M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $217.09M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $251.91M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $159.02M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $140.82M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $41.81M | Mar 4, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.25M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $104.20M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $113.97M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $98.50M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $47.75M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $41.03M | Mar 4, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.33M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $112.89M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $137.94M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $60.53M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $93.07M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $776.0K | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $3.16M | Mar 8, 2023 |
| FY2021 | Dec 31, 2018 | $5.95M | Mar 4, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.82M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $12.82M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $12.82M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Feb 27, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($248.99M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($189.99M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($134.25M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($84.72M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($41.91M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($21.35M) | Mar 4, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.71M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $11.35M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $12.98M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $19.47M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $105.83M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $18.08M | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | $12.14M | Mar 4, 2022 |
| FY2021 | Dec 31, 2018 | $1.28M | Mar 4, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.58M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $53.31M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $53.01M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $52.71M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $29.37M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $30.98M | Mar 4, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 8, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 8, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 61.75M | Feb 27, 2024 |
| FY2023 | Dec 31, 2022 | 55.63M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 54.18M | Mar 8, 2023 |